Modality
Cell Therapy
MOA
CD47i
Target
IL-13
Pathway
Innate Imm
NBASCRC
Development Pipeline
Preclinical
~Feb 2017
→ ~May 2018
Phase 1
~Aug 2018
→ ~Nov 2019
Phase 2
Feb 2020
→ Jan 2029
Phase 2Current
NCT06568752
2,578 pts·CRC
2020-02→2025-08·Active
NCT03331629
265 pts·CRC
2020-04→2029-01·Completed
2,843 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-08-257mo agoPh3 Readout· CRC
2029-01-182.8y awayPh3 Readout· CRC
Trial Timeline
2020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029
P2/3
Active
P2/3
Complet…
Catalysts
Ph3 Readout
2025-08-25 · 7mo ago
CRC
Ph3 Readout
2029-01-18 · 2.8y away
CRC
ActiveCompleted|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06568752 | Phase 2/3 | CRC | Active | 2578 | CR |
| NCT03331629 | Phase 2/3 | CRC | Completed | 265 | PANSS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Nirarelsin | Johnson & Johnson | Phase 2 | PRMT5 | |
| Cevizanubrutinib | Johnson & Johnson | Preclinical | FcRn | |
| Lisonaritide | Eli Lilly | Phase 3 | IL-13 | |
| Ceviglumide | Roche | NDA/BLA | B7-H3 | |
| NVS-1475 | Novartis | Phase 2 | Menin | |
| Sovarapivir | AbbVie | Phase 2/3 | IL-13 | |
| AZN-6294 | AstraZeneca | Phase 2/3 | APOC3 | |
| Ceviderotide | Novo Nordisk | Preclinical | IL-13 | |
| Zenonesiran | GSK | Preclinical | DLL3 | |
| DSN-3066 | Daiichi Sankyo | Phase 3 | IL-13 |